期刊
ALZHEIMERS & DEMENTIA
卷 18, 期 12, 页码 2669-2686出版社
WILEY
DOI: 10.1002/alz.12756
关键词
Alzheimer's disease; appropriate use recommendations; blood-based biomarkers; diagnosis; prognosis
资金
- ADx
- AVID Radiopharmaceuticals
- Biogen
- Eli Lilly
- Eisai
- Fujirebio
- GE Healthcare
- Pfizer
- Roche
- AC-Immune
- Axon Neurosciences
- Brainstorm Therapeutics
- Celgene
- EIP Pharma
- PeopleBio
- Toyama
- Vivoryon
- NIH [U19AG063911, U54NS092089, R01AG038791, U01AG045390, P01AG036694, R01AG053798, R01AG054029, U24AG057437, R01AG061848, R01AG063689]
- Tau Research Consortium
- Bluefield Project to Cure FTD
- University of California Cures ADProgram
- Association for Frontotemporal Degeneration
- CBDSolutions
- Alzheimer's Drug Discovery Foundation
- Alzheimer's Association
- Regeneron
- Alzheimer's Association [ZEN-21-848216]
- American College of Radiology
- Rainwater Charitable Foundation
- Alliance for Therapeutics in Neurodegeneration
- Life Molecular Imaging
- Genentech
Blood-based markers have the potential to revolutionize the diagnosis and prognosis of Alzheimer's disease and improve the design of clinical trials. However, further research is needed before widespread use.
Blood-based markers (BBMs) have recently shown promise to revolutionize the diagnostic and prognostic work-up of Alzheimer's disease (AD), as well as to improve the design of interventional trials. Here we discuss in detail further research needed to be performed before widespread use of BBMs. We already now recommend use of BBMs as (pre-)screeners to identify individuals likely to have AD pathological changes for inclusion in trials evaluating disease-modifying therapies, provided the AD status is confirmed with positron emission tomography (PET) or cerebrospinal fluid (CSF) testing. We also encourage studying longitudinal BBM changes in ongoing as well as future interventional trials. However, BBMs should not yet be used as primary endpoints in pivotal trials. Further, we recommend to cautiously start using BBMs in specialized memory clinics as part of the diagnostic work-up of patients with cognitive symptoms and the results should be confirmed whenever possible with CSF or PET. Additional data are needed before use of BBMs as stand-alone diagnostic AD markers, or before considering use in primary care.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据